Detalhe da pesquisa
1.
Latent variable indirect response modeling of clinical efficacy endpoints with combination therapy: application to guselkumab and golimumab in patients with ulcerative colitis.
J Pharmacokinet Pharmacodyn
; 50(2): 133-144, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36648595
2.
Variability and uncertainty: interpretation and usage of pharmacometric simulations and intervals.
J Pharmacokinet Pharmacodyn
; 49(5): 487-491, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35927373
3.
Improving categorical endpoint longitudinal exposure-response modeling through the joint modeling with a related endpoint.
J Pharmacokinet Pharmacodyn
; 49(3): 283-291, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34800232
4.
Integrated pharmacokinetic/viral dynamic model for daclatasvir/asunaprevir in treatment of patients with genotype 1 chronic hepatitis C.
Acta Pharmacol Sin
; 39(1): 140-153, 2018 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-28880015
5.
Modeling near-continuous clinical endpoint as categorical: application to longitudinal exposure-response modeling of Mayo scores for golimumab in patients with ulcerative colitis.
J Pharmacokinet Pharmacodyn
; 45(6): 803-816, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30377888
6.
Joint longitudinal model development: application to exposure-response modeling of ACR and DAS scores in rheumatoid arthritis patients treated with sirukumab.
J Pharmacokinet Pharmacodyn
; 45(5): 679-691, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29961161
7.
A comprehensive evaluation of exposure-response relationships in clinical trials: application to support guselkumab dose selection for patients with psoriasis.
J Pharmacokinet Pharmacodyn
; 45(4): 523-535, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29549540
8.
Improvement in latent variable indirect response modeling of multiple categorical clinical endpoints: application to modeling of guselkumab treatment effects in psoriatic patients.
J Pharmacokinet Pharmacodyn
; 44(5): 437-448, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-28634654
9.
Challenges in longitudinal exposure-response modeling of data from complex study designs: a case study of modeling CDAI score for ustekinumab in patients with Crohn's disease.
J Pharmacokinet Pharmacodyn
; 44(5): 425-436, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-28623612
10.
Improvement in latent variable indirect response joint modeling of a continuous and a categorical clinical endpoint in rheumatoid arthritis.
J Pharmacokinet Pharmacodyn
; 43(1): 45-54, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26553114
11.
Information contributed by meta-analysis in exposure-response modeling: application to phase 2 dose selection of guselkumab in patients with moderate-to-severe psoriasis.
J Pharmacokinet Pharmacodyn
; 41(3): 239-50, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24852042
12.
Latent variable indirect response joint modeling of a continuous and a categorical clinical endpoint.
J Pharmacokinet Pharmacodyn
; 41(4): 335-49, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-25038623
13.
Latent variable indirect response modeling of categorical endpoints representing change from baseline.
J Pharmacokinet Pharmacodyn
; 40(1): 81-91, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23275019
14.
Landmark and longitudinal exposure-response analyses in drug development.
J Pharmacokinet Pharmacodyn
; 44(5): 503-507, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-28730565
15.
Pharmacokinetic/Pharmacodynamic Analysis of Guselkumab for Treatment of Palmoplantar Pustulosis: Clinical Implications of Guselkumab Dose, Disease Severity, and Smoking in Japanese Patients.
J Clin Pharmacol
; 62(2): 182-189, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34382209
16.
Population Pharmacokinetic and Exposure-Response Model Simulations: Predicted Exposure and Efficacy for Maintenance Doses of Intravenous Golimumab Every 6 or 8 Weeks in Patients With Moderately to Severely Active Rheumatoid Arthritis.
Clin Ther
; 44(3): 457-464.e2, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35183373
17.
Erratum to: Improvement in latent variable indirect response joint modeling of a continuous and a categorical clinical endpoint in rheumatoid arthritis.
J Pharmacokinet Pharmacodyn
; 43(1): 55, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26597150
18.
Informative dropout modeling of longitudinal ordered categorical data and model validation: application to exposure-response modeling of physician's global assessment score for ustekinumab in patients with psoriasis.
J Pharmacokinet Pharmacodyn
; 38(2): 237-60, 2011 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-21327538
19.
Bounded outcome score modeling: application to treating psoriasis with ustekinumab.
J Pharmacokinet Pharmacodyn
; 38(4): 497-517, 2011 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-21688068
20.
Confirmatory analysis for phase III population pharmacokinetics.
Pharm Stat
; 10(1): 14-26, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-20041468